替吉奥维持治疗晚期结直肠癌的临床效果(4)
[15] 张星霖，宫帅，贾伟丽.替吉奥联合三维适形放疗治疗局部晚期直肠癌的疗效观察[J].中国肿瘤临床与康复，2013，20(7)： 756-758.
[16] 万德森.老年人结直肠癌治疗策略[J].中国肿瘤临床与康复，2013，20(1)： 91-92.
[17] Nakayama G，Kodera Y，Yokoyama H，et al. Modified FOLFOX6 with oxaliplatin stop-and-go stategy and oral S-1 maintennance therapy in advanced colorectal cancer： CCOG-0704 study [J]. Int J Clin Oncol，2011，16(5)：506-511.
[18] Díaz-Rubio E，Gómez-Espaa A，Massutí B，et al.First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer：the phase Ⅲ MACRO TTD study[J]. Oncologist， 2012，17(1)：15-25.
[19] Christophe Tournigand，Benoist Chibaudel，Benoit Samson，et al. Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM； OPTIMOX3)： a randomised，open-label，phase 3 trial [J]. Lancet Oncol，2015，16(15)：1493-1505.
[20] Simkens LH，van Tinteren H，May A，et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3)：a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group[J]. Lancet，2015，385(9980)：1843-1852.
(收稿日期：2016-01-07 本文编辑：赵鲁枫) (周易 王兰君 李萍 范丽昕)
[16] 万德森.老年人结直肠癌治疗策略[J].中国肿瘤临床与康复，2013，20(1)： 91-92.
[17] Nakayama G，Kodera Y，Yokoyama H，et al. Modified FOLFOX6 with oxaliplatin stop-and-go stategy and oral S-1 maintennance therapy in advanced colorectal cancer： CCOG-0704 study [J]. Int J Clin Oncol，2011，16(5)：506-511.
[18] Díaz-Rubio E，Gómez-Espaa A，Massutí B，et al.First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer：the phase Ⅲ MACRO TTD study[J]. Oncologist， 2012，17(1)：15-25.
[19] Christophe Tournigand，Benoist Chibaudel，Benoit Samson，et al. Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM； OPTIMOX3)： a randomised，open-label，phase 3 trial [J]. Lancet Oncol，2015，16(15)：1493-1505.
[20] Simkens LH，van Tinteren H，May A，et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3)：a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group[J]. Lancet，2015，385(9980)：1843-1852.
(收稿日期：2016-01-07 本文编辑：赵鲁枫) (周易 王兰君 李萍 范丽昕)